Drug Trial Radar · NCT00152022
Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.
Last checked: Nov 19, 2026Latest source record: Jul 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
412
Actual
Start
Apr 25, 2005
Primary completion
Nov 4, 2005
Study completion Nov 4, 2005
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 9, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD. The study will also look at how SPD465 affects the participants sleep and how they perceive their quality of life.
Conditions
- Attention Deficit Disorder With Hyperactivity
Interventions
Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)Time frame: Baseline (following ADHD medication washout of 7-28 days)
- The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)Time frame: Week 1
- The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)Time frame: Week 2
- The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)Time frame: Week 3
- The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)Time frame: Week 4
- The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)Time frame: Week 5
- The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)Time frame: Week 6
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.